Available after the sale.
The development and tech support team that built the product will be introduced on the introduction call. They remain available after completion and can fully support delivery of the five-year roadmap.
Launch-ready on day one.
This product site is built on Next.js with a working chair-to-lab demo on sample data, ready to deploy on the exact-match .com.
- Exact-match brushbiopsy.com domain
- Product site with recreated clinician dashboard, sample-tracking map, triage queue and report viewer
- Working MVP demo at /demo: track, triage, sign off and recall on sample data
- Brand system, offer handling, analytics and privacy plumbing already wired
Every brush sample tracked until the loop is closed.
Brush biopsy has a dental billing code, a rising disease burden and growing AI cytology research, yet most practices still post a sample to one closed laboratory and track the result on paper. BrushBiopsy is the workflow layer: orders, chain of custody, a reader triage queue, structured reports and a recall register.
- Working MVP: kit orders, chain-of-custody tracking, triage queue, reader sign-off, report and recall register on sample data
- Lab-neutral by design: any accredited cytology laboratory can join
- Regulatory wedge: the workflow layer ships first; the AI prioritisation module follows through formal submissions
- Clear path to a cervical self-sample triage module in Year 3
An open rail for a test that has a code but no infrastructure.
Oral cancer is rising: 389,846 new lip and oral cavity cancers worldwide in 2022 (GLOBOCAN), about 60,480 US oral cavity and pharynx cancers expected in 2026 (American Cancer Society) and a record 10,825 UK mouth cancer diagnoses a year (Oral Health Foundation). Dentists see the lesions first.
The roadmap keeps qualified readers in charge: workflow and tracking first, AI-assisted cell prioritisation through proper submissions, and a recall register that also produces the outcome evidence payers say the category lacks.
- Kit ordering, barcode chain of custody and courier tracking for dental groups
- Partner-lab triage queue with structured reporting and reader sign-off
- Recall register for atypical results, with referral and histology closure
- Whole-slide image viewer with AI-assisted cell prioritisation, validated with partner labs
- Regulatory submissions planned (US De Novo/510(k), UKCA, IVDR) before any clinical use of the AI module
- Practice-management and lab-system integrations
- Multi-lab network across the UK, US and one high-burden region
- Cervical self-sample triage module for HPV-positive follow-up
- Outcome dataset (brush result versus histology) for payers and guideline bodies
Illustrative projections
| Metric | Y1 | Y2 | Y3 | Y4 | Y5 |
|---|---|---|---|---|---|
| Customers | 6 | 24 | 60 | 120 | 210 |
| Revenue | $108k | $583k | $1.8M | $4.1M | $8.1M |
| Gross margin | 60% | 67% | 73% | 77% | 80% |
| Opex | $1.1M | $1.9M | $2.8M | $4.0M | $5.4M |
| EBITDA | −$1.0M | −$1.5M | −$1.5M | −$867k | $1.1M |
Assumptions
- A customer is a dental group or dental support organisation, an independent cytology laboratory, or a regional screening programme. Blended annual revenue of $36k per customer in Year 1 (platform subscription plus a per-sample workflow fee), rising 8% a year as more sites and sample volume are covered.
- New customers: 6, 18, 38, 65 and 100 in Years 1 to 5, starting with UK and US dental groups that already bill brush biopsies (CDT D7288 in the US) and one partner laboratory per region.
- 8% annual logo churn. Customer acquisition cost of $14k per new customer, led by a chair-to-lab pilot rather than field sales.
- Gross margin rises from 60% to 80% as courier, kit and hosting costs are spread over volume. Laboratory reading is performed and billed by partner laboratories, not by BrushBiopsy.
- R&D, quality, regulatory and G&A budget of $1.0M rising to $4.0M by Year 5, including the cost of regulatory submissions for the AI module. No outside funding is assumed or implied.
Meet the development and tech support team on your introduction call. They stay with the product after the sale, ready to back your five-year roadmap.